Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

Summary

This study is to evaluate the safety and efficacy of the study drug compared to placebo in the treatment of cognitive impairment in men with schizophrenia.

Timeline

Start

2008-10

Primary completion

2009-06

Completion

2009-06

Outcome

Missed primary endpoint

registry analysis (superiority or other test); MK5757 vs Placebo; p = 0.277; constrained Longitudinal Data Analysis NCT00848484 ↗

Drugs

Indications